Anjali Jain, PhD

Research Scientist, Hematology/Oncology

Email:anjali.jain@cshs.org
Phone:(310) 423-7376
Fax:(310) 423-7699

Institute Affiliation

Samuel Oschin Comprehensive Cancer Institute

Academic Appointments

Assistant Professor, Medicine

Research Focus

Response and resistance mechanisms of therapeutics targeting kinase signaling pathways in solid tumors utilizing prostate cancers as model systems. Molecular biology of hormone refractory prostate cancer progression with a focus on discovery and development of novel therapeutics.

Research Contributions

Discovery of EMP-1 as a biomarker of gefitinib resistance. Novel cross-talk mechanisms between EGFR and PPARg signaling networks.

Current investigations include:

Role of Epithelial to mesenchymal transitions in targeted therapy response. Monitoring therapeutic response with phosphoproteomics based signatures. Androgen receptor signaling.

Selected Publications

  1. Laux I, Jain A, Singh S, Agus DB: Epidermal growth factor receptor dimerization status determines skin toxicity to HER-kinase targeted therapies. Br. J. Cancer, 94(1): 85-92, 2006
  2. Shazer RL, Jain A, Galkin AV, Cinman N, Nguyen KN, Natale RB, Gross M, Green L, Bender LI, Holden S, Kaplan L, Agus DB: Raloxifene, an oestrogen-receptor-beta-targeted therapy, inhibits androgen-independent prostate cancer growth: results from preclinical studies and a pilot phase II clinical trial. BJU Int., 97(4): 691-7, 2006
  3. Jain A, Tindell CA, Laux I, Hunter JB, Curran J, Galkin A, Afar DE, Aronson N, Shak S, Natale RB, Agus DB: Epithelial membrane protein-1 is a biomarker of gefitinib resistance. Proc. Natl. Acad. Sci. U.S.A., 102(33): 11858-63, 2005
  4. Jain A, Agus DB: PPARgamma signaling: one size fits all?. Cell Cycle, 3(11): 1352-4, 2004
  5. Hedvat M, Jain A, Carson DA, Leoni LM, Huang G, Holden S, Lu D, Corr M, Fox W, Agus DB: Inhibition of HER-kinase activation prevents ERK-mediated degradation of PPARgamma. Cancer Cell, 5(6): 565-74, 2004
  6. Jain A, Lam A, Vivanco I, Carey MF, Reiter RE: Identification of an androgen-dependent enhancer within the prostate stem cell antigen gene. Mol. Endocrinol., 16(10): 2323-37, 2002
print button
WP3